Cargando…
Inhibition of Glutamine Uptake Resensitizes Paclitaxel Resistance in SKOV3-TR Ovarian Cancer Cell via mTORC1/S6K Signaling Pathway
Ovarian cancer is a carcinoma that affects women and that has a high mortality rate. Overcoming paclitaxel resistance is important for clinical application. However, the effect of amino acid metabolism regulation on paclitaxel-resistant ovarian cancer is still unknown. In this study, the effect of a...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369036/ https://www.ncbi.nlm.nih.gov/pubmed/35955892 http://dx.doi.org/10.3390/ijms23158761 |
_version_ | 1784766333594894336 |
---|---|
author | Kim, Gyeongmi Jang, Se-Kyeong Kim, Yu Jin Jin, Hyeon-Ok Bae, Seunghee Hong, Jungil Park, In-Chul Lee, Jae Ho |
author_facet | Kim, Gyeongmi Jang, Se-Kyeong Kim, Yu Jin Jin, Hyeon-Ok Bae, Seunghee Hong, Jungil Park, In-Chul Lee, Jae Ho |
author_sort | Kim, Gyeongmi |
collection | PubMed |
description | Ovarian cancer is a carcinoma that affects women and that has a high mortality rate. Overcoming paclitaxel resistance is important for clinical application. However, the effect of amino acid metabolism regulation on paclitaxel-resistant ovarian cancer is still unknown. In this study, the effect of an amino acid-deprived condition on paclitaxel resistance in paclitaxel-resistant SKOV3-TR cells was analyzed. We analyzed the cell viability of SKOV3-TR in culture conditions in which each of the 20 amino acids were deprived. As a result, the cell viability of the SKOV3-TR was significantly reduced in cultures deprived of arginine, glutamine, and lysine. Furthermore, we showed that the glutamine-deprived condition inhibited mTORC1/S6K signaling. The decreased cell viability and mTORC1/S6K signaling under glutamine-deprived conditions could be restored by glutamine and α-KG supplementation. Treatment with PF-4708671, a selective S6K inhibitor, and the selective glutamine transporter ASCT2 inhibitor V-9302 downregulated mTOR/S6K signaling and resensitized SKOV3-TR to paclitaxel. Immunoblotting showed the upregulation of Bcl-2 phosphorylation and a decrease in Mcl-1 expression in SKOV3-TR via the cotreatment of paclitaxel with PF-4708671 and V-9302. Collectively, this study demonstrates that the inhibition of glutamine uptake can resensitize SKOV3-TR to paclitaxel and represents a promising therapeutic target for overcoming paclitaxel resistance in ovarian cancer. |
format | Online Article Text |
id | pubmed-9369036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93690362022-08-12 Inhibition of Glutamine Uptake Resensitizes Paclitaxel Resistance in SKOV3-TR Ovarian Cancer Cell via mTORC1/S6K Signaling Pathway Kim, Gyeongmi Jang, Se-Kyeong Kim, Yu Jin Jin, Hyeon-Ok Bae, Seunghee Hong, Jungil Park, In-Chul Lee, Jae Ho Int J Mol Sci Article Ovarian cancer is a carcinoma that affects women and that has a high mortality rate. Overcoming paclitaxel resistance is important for clinical application. However, the effect of amino acid metabolism regulation on paclitaxel-resistant ovarian cancer is still unknown. In this study, the effect of an amino acid-deprived condition on paclitaxel resistance in paclitaxel-resistant SKOV3-TR cells was analyzed. We analyzed the cell viability of SKOV3-TR in culture conditions in which each of the 20 amino acids were deprived. As a result, the cell viability of the SKOV3-TR was significantly reduced in cultures deprived of arginine, glutamine, and lysine. Furthermore, we showed that the glutamine-deprived condition inhibited mTORC1/S6K signaling. The decreased cell viability and mTORC1/S6K signaling under glutamine-deprived conditions could be restored by glutamine and α-KG supplementation. Treatment with PF-4708671, a selective S6K inhibitor, and the selective glutamine transporter ASCT2 inhibitor V-9302 downregulated mTOR/S6K signaling and resensitized SKOV3-TR to paclitaxel. Immunoblotting showed the upregulation of Bcl-2 phosphorylation and a decrease in Mcl-1 expression in SKOV3-TR via the cotreatment of paclitaxel with PF-4708671 and V-9302. Collectively, this study demonstrates that the inhibition of glutamine uptake can resensitize SKOV3-TR to paclitaxel and represents a promising therapeutic target for overcoming paclitaxel resistance in ovarian cancer. MDPI 2022-08-06 /pmc/articles/PMC9369036/ /pubmed/35955892 http://dx.doi.org/10.3390/ijms23158761 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kim, Gyeongmi Jang, Se-Kyeong Kim, Yu Jin Jin, Hyeon-Ok Bae, Seunghee Hong, Jungil Park, In-Chul Lee, Jae Ho Inhibition of Glutamine Uptake Resensitizes Paclitaxel Resistance in SKOV3-TR Ovarian Cancer Cell via mTORC1/S6K Signaling Pathway |
title | Inhibition of Glutamine Uptake Resensitizes Paclitaxel Resistance in SKOV3-TR Ovarian Cancer Cell via mTORC1/S6K Signaling Pathway |
title_full | Inhibition of Glutamine Uptake Resensitizes Paclitaxel Resistance in SKOV3-TR Ovarian Cancer Cell via mTORC1/S6K Signaling Pathway |
title_fullStr | Inhibition of Glutamine Uptake Resensitizes Paclitaxel Resistance in SKOV3-TR Ovarian Cancer Cell via mTORC1/S6K Signaling Pathway |
title_full_unstemmed | Inhibition of Glutamine Uptake Resensitizes Paclitaxel Resistance in SKOV3-TR Ovarian Cancer Cell via mTORC1/S6K Signaling Pathway |
title_short | Inhibition of Glutamine Uptake Resensitizes Paclitaxel Resistance in SKOV3-TR Ovarian Cancer Cell via mTORC1/S6K Signaling Pathway |
title_sort | inhibition of glutamine uptake resensitizes paclitaxel resistance in skov3-tr ovarian cancer cell via mtorc1/s6k signaling pathway |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369036/ https://www.ncbi.nlm.nih.gov/pubmed/35955892 http://dx.doi.org/10.3390/ijms23158761 |
work_keys_str_mv | AT kimgyeongmi inhibitionofglutamineuptakeresensitizespaclitaxelresistanceinskov3trovariancancercellviamtorc1s6ksignalingpathway AT jangsekyeong inhibitionofglutamineuptakeresensitizespaclitaxelresistanceinskov3trovariancancercellviamtorc1s6ksignalingpathway AT kimyujin inhibitionofglutamineuptakeresensitizespaclitaxelresistanceinskov3trovariancancercellviamtorc1s6ksignalingpathway AT jinhyeonok inhibitionofglutamineuptakeresensitizespaclitaxelresistanceinskov3trovariancancercellviamtorc1s6ksignalingpathway AT baeseunghee inhibitionofglutamineuptakeresensitizespaclitaxelresistanceinskov3trovariancancercellviamtorc1s6ksignalingpathway AT hongjungil inhibitionofglutamineuptakeresensitizespaclitaxelresistanceinskov3trovariancancercellviamtorc1s6ksignalingpathway AT parkinchul inhibitionofglutamineuptakeresensitizespaclitaxelresistanceinskov3trovariancancercellviamtorc1s6ksignalingpathway AT leejaeho inhibitionofglutamineuptakeresensitizespaclitaxelresistanceinskov3trovariancancercellviamtorc1s6ksignalingpathway |